Latest Property Portfolio News

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

Hudson Investment Group signals potential corporate restructure as it explores sale and joint venture options for key Queensland and NSW properties.

The Star Entertainment Group has agreed to sell its Sydney Event Centre assets to Foundation Theatres for $60 million, marking a strategic shift in its property portfolio.

Anatara Lifesciences has been granted a key Australian patent for its GaRP gastrointestinal health product, reinforcing its intellectual property portfolio ahead of pivotal clinical trial results expected in March 2025.

IperionX has completed its inaugural end-to-end titanium powder production cycle using its proprietary HAMR process and secured exclusive rights to breakthrough titanium technologies, positioning itself for expanded manufacturing capacity and strong market demand.

CAQ Holdings Limited reported an 8% decrease in leasing revenue for the December 2024 quarter, as tenant negotiations continue amid uncertain government policies affecting the Hainan free trade port development.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.

Archer Materials has been granted a pivotal US patent for its Biochip technology, safeguarding its intellectual property and positioning the company for strategic entry into the lucrative US medical diagnostics market.

The GPT Group has forged a strategic partnership for Rouse Hill Town Centre and increased its ownership in Highpoint Shopping Centre to 25%, unlocking $176 million in net proceeds to reduce gearing and fuel future investments.

Mesoblast has raised A$260 million through a global private placement to fund the US commercial launch of its FDA-approved cell therapy Ryoncil® and accelerate clinical development in chronic low back pain.